Amarin Responds to Inaccurate and Misleading Statement by Sarissa
January 19, 2023 07:00 ET
|
Amarin Corporation plc
-- Board Refreshment Process Has Been Comprehensive, Independent and Transparent; Sarissa’s Candidates Are Not Qualified Versus Recently Appointed Board Members -- -- Amarin Recognizes Shareholder...
Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders
January 11, 2023 16:33 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (“Amarin” or the “Company”) today confirmed receipt of a requisition by Sarissa Capital...
Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
January 10, 2023 07:15 ET
|
Amarin Corporation plc
-- Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow and Continued Progress on European Reimbursements -- -- Amarin to Present at 41st...
Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
January 10, 2023 07:00 ET
|
Amarin Corporation plc
-- Dr. Stewart Brings More Than 30 Years of Cardiometabolic Academic and Industry Experience to Amarin’s Board –- -- Ongoing Board Refreshment Program Has Led to Approximately 70% New Independent...
Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 14, 2022 07:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is...
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
December 07, 2022 08:30 ET
|
Amarin Corporation plc
-- Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 ---- Swissmedic Approval Underpins Company’s Presence and Expansion in Switzerland as...
Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
November 15, 2022 07:00 ET
|
Amarin Corporation plc
-- VAZKEPA® Approved in Australia to Reduce the Risk of CV Events in Adult Statin-Treated Patients with High CV Risk with Elevated Triglycerides -- -- Marks Fifth Regulatory Approval for...
Amarin to Present at Jefferies London Healthcare Conference
November 09, 2022 08:00 ET
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is...
Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care
November 07, 2022 08:00 ET
|
Amarin Corporation plc
-- Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients -- -- PROMINENT Study Failed to Show CV Risk Reduction...
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
October 27, 2022 07:00 ET
|
Amarin Corporation plc
-- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of VAZKEPA® (icosapent ethyl) in England & Wales...